Cullinan Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Cullinan Therapeutics Stock-Based Compensation Growth & History (CGEM)
Cullinan Therapeutics's stock-based compensation was $36.0M for fiscal 2025.
View full Cullinan Therapeutics company overviewCullinan Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $36.0M | −$1.8M | −4.72% |
| 2024 | 2024-12-31 | $37.8M | $7.4M | +24.27% |
| 2023 | 2023-12-31 | $30.4M | $2.5M | +8.87% |
| 2022 | 2022-12-31 | $28.0M | $3.6M | +14.70% |
| 2021 | 2021-12-31 | $24.4M | $9.5M | +63.48% |
| 2020 | 2020-12-31 | $14.9M | — | — |
Cullinan Therapeutics quarterly stock-based compensation
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $8.4M | −$1.4M | −14.56% |
| Q1 2026 | 2026-03-31 | $7.6M | −$1.8M | −18.75% |
| Q4 2025 | 2025-12-31 | $7.3M | −$2.3M | −24.10% |
| Q3 2025 | 2025-09-30 | $9.5M | $37,000 | +0.39% |
| Q2 2025 | 2025-06-30 | $9.9M | −$646,000 | −6.13% |
| Q1 2025 | 2025-03-31 | $9.4M | $1.1M | +13.94% |
| Q4 2024 | 2024-12-31 | $9.6M | $2.1M | +28.13% |
| Q3 2024 | 2024-09-30 | $9.4M | $1.7M | +21.83% |
| Q2 2024 | 2024-06-30 | $10.5M | $2.6M | +32.99% |
| Q1 2024 | 2024-03-31 | $8.2M | $968,000 | +13.34% |
| Q4 2023 | 2023-12-31 | $7.5M | $6,000 | +0.08% |
| Q3 2023 | 2023-09-30 | $7.7M | $2.5M | +46.84% |
| Q2 2023 | 2023-06-30 | $7.9M | −$688,000 | −7.99% |
| Q1 2023 | 2023-03-31 | $7.3M | $694,000 | +10.57% |
| Q4 2022 | 2022-12-31 | $7.5M | −$4.6M | −38.14% |
| Q3 2022 | 2022-09-30 | $5.3M | $714,000 | +15.67% |
| Q2 2022 | 2022-06-30 | $8.6M | $4.4M | +106.67% |
| Q1 2022 | 2022-03-31 | $6.6M | $3.1M | +87.14% |
| Q4 2021 | 2021-12-31 | $12.1M | — | — |
| Q3 2021 | 2021-09-30 | $4.6M | — | — |
| Q2 2021 | 2021-06-30 | $4.2M | — | — |
| Q1 2021 | 2021-03-31 | $3.5M | — | — |
Cullinan Therapeutics stock-based compensation trends
Over the last five fiscal years, Cullinan Therapeutics's stock-based compensation increased from $14.9M to $36.0M, a change of $21.1M. The latest reported quarter, Q2 2026, shows $8.4M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cullinan Therapeutics source filings ↗